logo.PNG
ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection
25 janv. 2022 05h06 HE | Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir...